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Cell signalingHepatocellular carcinoma represents one of the most-rapidly spreading cancers in the world. In the majority of
cases, an inﬂammation-driven ﬁbrosis or cirrhosis precedes the development of the tumor. During malignant
transformation, the tumor microenvironment undergoes qualitative and quantitative changes that modulate
the behavior of the malignant cells. A key constituent for the hepatic microenvironment is the small leucine-
rich proteoglycan decorin, known to interfere with cellular events of tumorigenesis mainly by blocking various
receptor tyrosine kinases (RTK) such as EGFR, Met, IGF-IR, PDGFR and VEGFR2. In this study, we characterized
cell signaling events evoked by decorin deﬁciency in two experimental models of hepatocarcinogenesis using
thioacetamide or diethyl nitrosamine as carcinogens. Genetic ablation of decorin led to enhanced tumor occur-
rence as compared to wild-type animals. These ﬁndings correlated with decreased levels of the cyclin-
dependent kinase inhibitor p21WAF1/CIP1 and a concurrent elevation in retinoblastoma protein phosphorylation
via cyclin dependent kinase 4. Decreased steady state p21Waf1/Cip1 levels correlated with enhanced expression
of transcription factor AP4, a known transcriptional repressor of p21Waf1/Cip1, and enhanced c-Myc protein levels.
In addition, translocation of β-catenin was a typical event in diethyl nitrosamine-evoked tumors. In parallel, de-
creased phosphorylation of both c-Myc and β-catenin was observed in Dcn−/− livers likely due to the hindered
GSK3β-mediated targeting of these proteins to proteasomal degradation. We discovered that in a genetic back-
ground lacking decorin, four RTKswere constitutively activated (phosphorylated), including three known targets
of decorin such as PDGFRα, EGFR, IGF-IR, and a novel RTKMSPR/RON. Our ﬁndings provide powerful genetic ev-
idence for a crucial in vivo role of decorin during hepatocarcinogenesis as lack of decorin in the liver and hepatic
stroma facilitates experimental carcinogenesis byproviding an environmentdevoid of this potent pan-RTK inhib-
itor. Thus, our results support future utilization of decorin as an antitumor agent in liver cancer.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Hepatocellular carcinoma (HCC) represents themost frequent type of
primary liver tumors, and it is the third most common fatal malignancy
disease worldwide (El-Serag and Rudolph, 2007). The highest HCC inci-
dence and mortality are observed in Eastern Asia and central Africa, but
its frequency has been rapidly increasing in Europe and in the United; RTK, receptor tyrosine kinase;
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ights reserved.States in the last decades. The major risk factors are hepatitis B and C
infection, aﬂatoxin B1 intake from contaminated food and excessive
alcohol abuse (Llovet et al., 2003; Sherman, 2010). Primary HCC often
evolves on cirrhotic or chronic inﬂammation induced ﬁbrotic back-
ground, although this is not essential for tumor formation.
The extracellular matrix (ECM) is an acellular compartment of
organs, made of macromolecules providing support for the cells, they
embrace. It is a key participant in the tissue speciﬁc organization of
cells and the establishment of their differentiated function. ECM
together with the nonparenchymal cells creates the microenvironment
for the parenchymal cells in the tissues. The phenotype and behavior of
parenchymal cells are inﬂuenced by their interrelationship with the
stromal elements in a great extent. However, not only differentiated,
but also malignant phenotype is proved to be driven by the microenvi-
ronment of cancer cells, including hepatomas. Their growth, local inva-
sion and metastatic ability all depend on their microenvironment.
During malignant transformation, the tumorous ECM undergoes
qualitative and quantitative changes. As a result, the matrix is capable
to provide the proper environment for tumor progression. Accordingly,
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ter understanding of the relationship between the tumor and its matrix.
Decorin is a member of the small leucine-rich proteoglycan (SLRP)
gene family (Iozzo and Murdoch, 1996; Iozzo, 1999; Iozzo et al., 2011)
that is expressed in the stroma of various forms of cancer (Iozzo and
Cohen, 1993) and thus has been recently proposed to act as a guardian
from the matrix (Neill et al., 2012b), in analogy to p53, the guardian of
the genome. Although this proteoglycan is ubiquitously expressed,
practically no cells of epithelial origin synthesize it. This implies that
decorin is a mesenchyme-speciﬁc gene product and that it exerts its ef-
fects in a paracrine fashion on endothelial and epithelial cells including
cancer cells. Functionally, soluble and matrix-bound decorin modulate
various biological processes including collagen ﬁbrillogenesis, wound
healing, myogenesis, bone physiology, stem cell biology, immunity, an-
giogenesis and ﬁbrosis (Reed and Iozzo, 2002; Robinson et al., 2005;
Zhang et al., 2009; Seidler et al., 2011; Ichii et al., 2012; Neill et al.,
2012a, 2013; Brandan and Gutierrez, 2013; Chen and Birk, 2013;
Dunkman et al., 2013; Sofeu Feugaing et al., 2013). Initially identiﬁed
as a natural inhibitor of transforming growth factor-β (Yamaguchi
et al., 1990; Ruoslahti and Yamaguchi, 1991), soluble decorin is emerg-
ing as a pan-RTK inhibitor targeting amultitude of RTKswith various af-
ﬁnities, including EGFR, Met, IGF-IR, VEGFR2 and PDGFR (Iozzo, 1999;
Schonherr et al., 2005; Schaefer et al., 2007; Goldoni et al., 2009; Iozzo
et al., 2011; Khan et al., 2011; Nikitovic et al., 2012; Schaefer and
Iozzo, 2012; Seidler, 2012; Baghy et al., 2013; Buraschi et al., 2013;
Morrione et al., 2013). Besides initiating signaling, this decorin/RTK in-
teraction can induce caveosomal internalization and receptor degrada-
tion (Zhu et al., 2005).
Notably, a combined genetic ablation of decorin and of the tumor
suppressor p53 induces the formation of early and aggressive T-cell
lymphomas that lead to a premature demise of the compound mice
(Iozzo et al., 1999a). These genetic studies are further supported by ge-
netic evidence where loss of the decorin gene is permissive for tumori-
genic growth of intestinal tumors with a concurrent increase in the
levels of β-catenin (Bi et al., 2008, 2012). Conversely, decorin delivered
via adenoviral-mediated gene transduction or systemic administration
of recombinant protein to several tumor xenografts, such as breast
and prostate carcinomas, inhibits tumorigenic growth (Reed et al.,
2002, 2005; Tralhao et al., 2003; Araki et al., 2009; Hu et al., 2009;
Buraschi et al., 2012).
A healthy liver contains only a small amount of decorin deposited
around the central veins and portal tracts. However, an increased depo-
sition of decorin was observed in the connective tissue septa during
ﬁbrogenesis (Dudas et al., 2001; Baghy et al., 2011). In hepatocellular
carcinoma, deregulation of several signaling pathways has been de-
scribed involving RAS/MAPK, IGF, HGF/MET, WNT/β-catenin, EGFR,
VEGFR and PDGFR (Villanueva et al., 2007). The observation that
decorin affects multiple signaling pathways emanating from various
RTKs together with its ability to downregulate β-catenin andMyc levels
(Buraschi et al., 2010) and to concurrently induce p21WAF1/CIP1 (Santra
et al., 1997), prompted us to investigate the role of decorin in mouse
models of hepatocarcinogenesis evoked by TA or DEN. We found that
a genetic background lacking one single SLRP caused a constitutive acti-
vation of various RTKs thus providing a mechanistic explanation for the
increased incidence of hepatocellular carcinomas in decorin-null livers
following experimental carcinogenesis.
2. Results
2.1. Decorin-null mice are more susceptible to experimentally-induced
liver cancer
Metabolization of thioacetamide (TA) in hepatocytes via cyto-
chrome p450 causes ﬁbrosis, and subsequently hepatic cirrhosis. Thus,
chronic TA exposure provokes hyper-regeneration of hepatocytes initi-
ating hepatocarcinogenesis in the cirrhotic liver (Becker, 1983; Camus-Randon et al., 1996) (Fig. 1A,B). TA-induced tumors showed abundant
cytoplasm with strong eosinophilic staining, and were surrounded by
a connective tissue capsule. In contrast, high dose of diethyl nitrosamine
(DEN) causes DNA mutations directly without evoking overt ﬁbrotic
changes (Heindryckx et al., 2009) (Fig. 1C,D). These tumor cells had nar-
row basophilic cytoplasm, and often invaded blood vessels.
Thioacetamide treatment induced liver tumor in ~93% of the mice
lacking the decorin gene in contrast to only ~22% tumor prevalence ob-
served in wild-type counterparts (n = 15 each, p b 0.001, Fig. 1E).
Moreover, Dcn−/−mice developed more tumors upon DEN treatment
as compared towild type (44% vs. 27%) (Fig. 1F), although the difference
did not reach statistical signiﬁcance (n = 10, p = 0.12). In parallel, sig-
niﬁcantly higher tumor volume was calculated in Dcn−/− animals than
that of wild type ones treated with TA (100.4 mm3 vs. 7.6 mm3 respec-
tively (p b 0.01)) as well as DEN (23.7 mm3 tumor volume in knockout
and 3.4 mm3 inwild typemice) (Fig. 1G). Thus, ablation of decorin sen-
sitizes liver for tumor formation, and this effect is more pronounced in
hepatocarcinogenesis with a cirrhotic background such as that induced
by TA.
2.2. Qualitative and quantitative changes of decorin in TA- and
DEN-induced tumors
Under unchallenged conditions, decorinwas primarily located in the
peri-portal areas and around the central veins of the liver (Fig. 2A,B). As
thioacetamide induces cirrhosis and thus a stromal activation, the
amount of decorin seemed to be increased in TA-treated livers of wild
type animals as detected by immunostaining (Fig. S1, Fig. 2C,D). Accu-
mulation of decorin was seen in ﬁbrotic septa, and focal deposits were
also observed in the tumor stroma (Fig. 2C,D). The immunodistribution
of decorin was overall similar in DEN- and TA-induced tumors (Fig. 2E,
F). Tumor foci were surrounded bywell-deﬁned deposits of immunore-
active decorin. Interestingly, we observed not only quantitative changes
but also qualitative changes in the glycanation of decorin. Unlike control
samples where decorin appeared as a smear between 60 and 80 kDa,
the proteoglycan in TA-treated livers was signiﬁcantly retarded and
centered at ~90 kDa (Fig. 2G). DEN exposure also caused a shift toward
higher molecular mass, although to a lesser degree (Fig. 2G). Notably,
quantiﬁcation of several experiments showed a signiﬁcant induction
of high molecular weight decorin content in both experimental animal
models (p b 0.001 and p b 0.05, respectively; Fig. 2H). These observa-
tions suggest that the expression of decorin is dynamically modulated
during hepatic carcinogenesis, especially in the TA-driven tumors
where the stroma plays a more prominent role than in DEN-driven
tumors.
2.3. Lack of decorin accelerates cell cycle progression
Next, we investigated the status of the cyclin-dependent kinase in-
hibitor p21Waf1/Cip1 since lack of decorin prevents its upregulation in
TA-induced liver cancer (Baghy et al., 2013). In control animals, low
levels of p21Waf1/Cip1 were detected by immunostaining with no appre-
ciable differences between wild-type and decorin-deﬁcient livers
(Fig. S2). Upon TA treatment, amarked induction of p21Waf1/Cip1was ob-
served in the wild-type samples (Fig. 3A, B). Hepatocytes, cells of the
connective tissue and tumor cells displayed intense positive staining.
In contrast, no accumulation could be detected in tumor cells lacking
decorin gene (Fig. 3E, F). Diethyl nitrosamine increased the amount of
p21Waf1/Cip1 as well (Fig. 3C, D), but decorin deﬁciency had less impact
on this process, as a considerable immunopositivity was observed in
Dcn−/− tumor cell nuclei (Fig. 3G,H).
Next, we performed qPCR for the genes encoding p21Waf1/Cip1
(CDKN1A) and the transcription factor AP4 (TFAP4), a c-MYC-inducible
basic helix–loop–helix leucine-zipper transcription factor that represses
CDKN1A expression. TA andDEN induced a 140-fold and a 20-fold eleva-
tion of CDKN1A, respectively, when compared to control samples
Fig. 1.Representative histological images of normal and tumorous livers induced by thioacetamide (TA) (A, B) orwith diethyl nitrosamine (DEN) (C, D). Tu = tumor, dashed lines indicate
tumor border. Asterisks show the same vein in different magniﬁcations. Scale bar = 200 μm for A and C, 100 μm for B and D. Bar charts represent the ratios of tumor-bearing
mice in experimental groups of wild-type and decorin gene knockout (Dcn−/−) mice with TA (E) and DEN treatment (F). N = 15 for TA and 10 for DEN-exposed groups. ***p b 0.001
(χ2- test). (G) Columns represent the tumor volume measured in livers exposed to TA and DEN. **p b 0.01. All data are expressed as mean ± SD.
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pression were detected in the decorin-null samples, regardless of the
carcinogen used (p b 0.05). In support of these data, we found a signif-
icant enhancement of TFAP4 gene expression in decorin-deﬁcient livers
when compared to wild type specimens (p b 0.01, Fig. 3J). TA and DEN
treatment decreased the level of AP4 in wild type animals by 52% andFig. 2. Changes of decorin level and localization in liver cancer. Immunostaining of decorin pro
exposed liver sections. Insets represent pictures taken within the tumor. Nuclei were counter
magniﬁcations. Scale bar = 100 μm for A, C and E, 50 μm for B, D and F, 15 μm for insets. R
Ponceau-stainingwas applied as loading control. (H) Diagrams show the decorin content at 2 di
*p b 0.05; ***p b 0.001.17% respectively. Thus, decorin deﬁciency leads to a marked arrest of
CDKN1A expression during experimental carcinogenesis, especially fol-
lowing TA treatment, with a concurrent induction of TFAP4.
To determine the exact point where p21Waf1/Cip1 interfered with the
cell cycle in our experimental model, different phosphorylation sites of
the retinoblastoma protein (Rb)were checked by immunoblottingwithteoglycan (red) in control (A, B), thioacetamide (TA) (C, D) and diethyl nitrosamine (E–F)
stained with DAPI. Tu = tumor. Asterisks show the same part of sections with different
epresentative image of the Western blot membrane (G) with decorin immunostaining.
fferent sizes in treated animals relative to control levels. Data are expressed asmean ± SD,
Fig. 3. Alterations in the p21WAF1/CIP1 level inwild-type and decorin gene knockout (Dcn−/−) mice n experimental hepatocarcinogenesis. Immunohistochemical analysis of p21WAF1/CIP1 in
tumorous liver sections after TAandDEN treatment inwild typemice (A–D)and indecorin-null (Dcn−/−)mice (E-H). Tu = tumor. Dashed lines show tumor borders. Scale bar = 100 μm
for A, C, E, G and 25 μm for B, D, F, H. Bar charts represent the relative CDKN1A (I) and TFAP4 (J) mRNA levels in livers of wild-type (WT) and decorin knockout (Dcn−/−) mice without
treatment (control = CTL) and after TA or DEN exposure. Data are expressed as mean ± SD. *p b 0.05; **p b 0.01.
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Unlike control samples, TA-induced liver tumors showed a marked Rb
phosphorylation at Ser780, known to be mediated through CDK4 activ-
ity, and this was more pronounced in the Dcn−/− samples vis-à-visFig. 4.Western blot analysis of retinoblastoma (Rb) phosphorylation at Ser780 and Thr821 inm
content of P-Rb (S780) (B) and P-Rb (T821) (C) in lysates of wild-type (WT) and decorin deﬁc
mean ± SD. *p b 0.05.wild-type samples (2.65 vs. 1.77-fold, p b 0.05, Fig. 4A). DEN exposure
resulted in 40% higher phospho-Rb at Ser780 level in decorin-null livers
vis-à-vis wild type samples (p b 0.05, Fig. 4A,B). Rb phosphorylation at
Thr821 is conducted exclusively by CDK2. Notably, tumors induced byurine livers. Ponceau-stainingwas used as loading control (A). Bar charts show the relative
ient (Dcn−/−) livers in control (CTL), TA and DEN-induced tumors. Data are expressed as
198 Z. Horváth et al. / Matrix Biology 35 (2014) 194–205either TA or DEN showed markedly elevated levels of P-Rb at Thr821,
but decorin deﬁciency did not affect this process (Fig. 4A, C). We con-
clude that a genetic background deprived of decorin favors cell cycle
progression of HCC by repressing AP4, inducing p21Waf1/Cip1, and en-
hancing phosphorylation of P-Rb at Ser780 by CDK4/CyclinD complex.
This series of events provides a mechanistic explanation for cells to by-
pass the restriction point at G1 and ultimately to affect cancer growth.
2.4. Major signaling pathways in HCC developed in a
decorin-null background
Next, we aimed to identify signaling pathways leading to enhanced
cell cycle progression in the HCC generated in decorin-null background.Fig. 5. Immunohistochemical analysis of various signaling proteins in wild-type (WT) and de
(A–H), phospho-c-Myc (I–P) and β-catenin (Q–X). Tu = tumor; dashed lines indicate tumor
Scale bar = 100 μm for A, C, E, G, I, K, M, O, Q, S, U, and W and 25 μm for B, D, F, H, J, L, N, P, RTo this end, we investigated several key signaling molecules known to
play important roles in hepatocarcinogenesis.
2.4.1. Changes of c-Myc
In normal liver, weak immunopositivity of c-Myc was detected both
in the cytoplasm and the nucleus (Fig. S2,E–H). Under basal conditions,
i.e., without exposure to carcinogens, decorin-deﬁcient livers showed a
~40% elevation in the amount of c-Myc (p b 0.01, Fig. S3A). Both TA and
DEN induced robust nuclear accumulation of c-Myc in both genotypes
as well (Fig. 5A–H), showing no difference in the strength of nuclear
staining between tumor cells and hepatocytes of the non-tumorous
region. In addition, in wild-type livers exposed to TA, an intensive
cytoplasmic c-Myc reaction was seen both in the tumor and in thecorin-null liver tumors (Dcn−/−) induced by TA or DEN. Representative images of c-Myc
borders. Asterisks represent the same part of the sections with different magniﬁcations.
, T, V, and X.
Fig. 6. Representative images of Western blot membranes probed for different signaling proteins (A, B). Ponceau-staining was applied as the loading control. Bar charts show the relative
levels of target proteins after densitometric analysis of the blots (C–K) normalized to Ponceau staining in livers of wild-type (WT) and decorin knockout (Dcn−/−) animals without treat-
ment (control = CTL), after TA or DEN exposure. Data are expressed as mean ± SD. *p b 0.05; **p b 0.01; ***p b 0.001.
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the decorin-deﬁcient tumor cells (Fig. 5E, F). OnWestern blots, TA expo-
sure resulted in c-Myc protein increase by 1.44-fold in wild-type sam-
ples, while decorin-null livers exhibited a 1.87-fold change (Fig. 6A,
Fig. S3A). In DEN-induced tumors of wild type animals, cytoplasmic
c-Myc protein levelswere less in tumor cell than that of the surrounding
tissue (Fig. 5C,D), and the reaction decreased further in Dcn−/− sections
(Fig. 5G,H). The total c-Myc level measured was 1.1 fold and 1.3 fold in
wild type and Dcn−/− livers, respectively (Fig. 6A, Fig. S3A).
To understand the changes in c-Myc localization, we tested the level
of phosphorylated c-Myc, which bears the signal of ubiquitination, thus
resides in the cytoplasm. By immunostaining, strong cytoplasmic posi-
tivity of tumor and non-tumorous cells of wild type liverswas observed,
regardless of the type of treatment (Fig. 5I–L). In contrast, decorin-null
tumor cells contained less phospho-protein compared to their sur-
rounding tissue (Fig. 5M–P). These results were conﬁrmed by quantiﬁ-
cation of Western blot analysis (Fig. 6A,C), showing decreased level of
phospho-c-Myc in Dcn−/− samples by 78% in control, 29% in TA-
treated and 44% in DEN-induced tumors relative to the total c-Myc
level (p b 0.05) (Fig. 6A,C).
2.4.2. The role of β-catenin
In control livers of both genotypes β-catenin was localized in the
membrane of hepatic cells (Fig. S2, M–P). Thioacetamide exposureincreased the amount of β-catenin, as strong immunostaining was ob-
served in the surrounding cirrhotic zones, especially within proliferat-
ing bile ducts (Fig. 5Q,R,U,V). However, hepatocytes and most of the
tumor cells retained their membranous β-catenin localization in both
genotypes, with the exception of a few cells displaying cytoplasmic or
weak nuclear signals (Fig. 5Q,R,U,V). In contrast, DEN induced marked
translocation of the protein into the nucleus. In addition an increase in
cytoplasmic immunopositivity was also detected (Fig. 5S,T,W,X). Total
protein amounts of β-catenin and its inactive phosphorylated form
were determined by immunoblottings. Unlike the control livers, the
total amount of β-catenin markedly increased both upon TA and DEN
exposure (Fig. 6A and Fig. S3B). In Dcn−/− livers, signiﬁcantly less inac-
tive β-catenin phosphorylated at Ser33/37/41 was seen as compared to
control (1 vs. 0.4-fold, p b 0.001, Fig. 6D) and in DEN-treated samples
(2.6 vs. 2.1-fold, p b 0.001, Fig. 6D). In contrast, after TA exposure of
Dcn−/− livers phospho-β-catenin level raised parallel with the increase
of total β-catenin, thus the ratio of phosphorylated/total protein
remained identical in Dcn−/− and wild type groups (Fig. 6D).
2.4.3. Activity of the Akt
Signal transduction mediated by Akt is known to play important
roles in carcinogenesis. Thus, we tested whether the level of Akt and
its active phosphorylated form would be altered in our experimental
animal model. In all conditions, we found no appreciable changes in
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practically undetectable (Fig. 6A,E). However, upon TA and DEN
exposure, its amount dramatically rose (Fig. 6A,E). Notably, decorin-
deﬁcient tumors exhibited signiﬁcantly higher level of phospho-Akt
than wild-type, ~40% and ~29% for TA- and DEN-driven tumors,
respectively (p b 0.05, Fig. 6E). Thus, also Akt pathway is activated
in the absence of decorin in this experimental animal model of
hepatocarcinogenesis.
2.4.4. Behavior of glycogen synthase kinase 3β (GSK3β)
GSK3β represents an important intersection among different signal-
ing pathways. In our experimental hepatocarcinogenesis model, the
total amount of GSK3β did not change upon decorin gene inactivation
in control and TA-treated groups, while DEN exposure resulted in 16%
higher protein level in Dcn−/− samples vis-à-vis wild-type (Fig. S3,D).
Inactive phosphorylated forms of GSK3α and βwere also tested by im-
munoblottings (Fig. 6B). Both α and β phospho-form levels markedly
increased upon TA treatment (Fig. 6B,F,G). Dcn−/− livers contained
27% less P-GSK3α than wild-type (p b 0.01, Fig. 6B,F). The same effect
was detected in DEN exposed livers, as decorin deﬁciency led to 35%
lower level of inactive GSK3α (p b 0.001). Interestingly, no difference
in phospho-GSK3β level was revealed between the genotypes either
in control or in carcinogen-treated groups; however, both TA and DEN
signiﬁcantly increased the level of the protein (Fig. 6B,G).
2.4.5. The key player Erk1/2
The most prominent changes in signaling occurred in Erk1/2. Total
amount of Erk1 and Erk2 proteins increased by ~2.5-fold and ~1.7-
fold after TA treatment respectively (Fig. S3, E,F). DEN exposure raised
the amount of Erk1/2 to ~1.2-fold. No signiﬁcant differences were
seen between the genotypes (Fig. S3, E,F). In wild-type animals, only
TA induced phosphorylation of Erk1/2 proteins, while DEN had no effect
on its activation level (Fig. 6B,H). Compared to controls, phospho-Erk1
was 2.3-fold vs. 3.6-fold higher in WT and Dcn−/− TA exposed samples
respectively (p b 0.01, Fig. 6H) relative to the total Erk1 amount.
Thioacetamide induced a 4.7 fold increase in Erk2 activation in Dcn−/−
livers in contrast to 1.24-fold detected in wild-type (p b 0.001,
Fig. 6H). Unlike DEN-treated wild-type samples, Dcn−/−mice showed
an activation of Erk1/2 as high as 2.9- and 5.3-fold, respectively
(p b 0.001, Fig. 6H). Thus, Erk1/2 pathway is constitutively activated
by a genetic background devoid of decorin.
2.5. Enhanced receptor tyrosine kinase activity in decorin-null mice
Next, we attempted to identify the putative receptors mediating the
downstream signaling described above. To this end, we utilized anti-
body arrays speciﬁc for phospho-receptor tyrosine kinases whichFig. 7. Changes of various active receptor tyrosine kinases in TA and DEN-evoked primary live
results obtained from densitometric analysis of array dots showing relative levels of phos
phospho-tyrosine positive control. Data are expressed as mean ± SD. *p b 0.05; ***p b 0.001.were successfully used before to detectMet as a novel ligand for decorin
protein core (Goldoni et al., 2009) and several RTKs for endorepellin
(Nystrom et al., 2009). We identiﬁed four RTKs, namely PDGFRα,
EGFR,MSPR (also known as RON) and IGF-IR that exhibited signiﬁcantly
higher levels in response to the absence of decorin (Fig. 7). Notably, we
found a 1.8 and 2.8 increase in tyrosine phosphorylation of PDGFRα in
Dcn−/− TA- and DEN-driven tumors, respectively (p b 0.001, Fig. 7).
Lack of decorin resulted in 1.5 and 3.6-times higher P-EGFR content
for TA- and DEN-evoked tumors, respectively (p b 0.05, Fig. 7).
We also found 1.4 and 1.9 increase in basal Tyr phosphorylation of
MSPR (HGF-like growth factor receptor, RON) in Dcn−/− TA- and
DEN-driven tumors (p b 0.05, Fig. 7). Interestingly, the amount of active
c-Met receptor increased upon both carcinogen exposure, but decorin
deﬁciency did not have any effect on the level of this RTK (data not
shown). The phospho-IGF-IR was detected in a low amount in TA and
DEN-induced tumors; however signiﬁcantly higher quantities were
measured in Dcn−/− livers than wild-type (p b 0.05, Fig. 7).
Collectively, our ﬁndings indicate that decorin deﬁciency results in
higher activation of various RTKs that could drive tumor cell growth.
3. Discussion
Hepatocarcinogenesis is a multi-step process involving different ge-
netic alterations and changes in signaling pathways that ultimately lead
to malignant transformation of the hepatocytes (Farber, 1984). In addi-
tion, not onlymolecular events occurring in tumor cells, but also their in-
teractions with macromolecules of the tumor microenvironment play a
crucial role in tumor progression and metastasis (Daley et al., 2008;
Marastoni et al., 2008; Hynes, 2009; Jarvelainen et al., 2009; Rozario
and DeSimone, 2010; Hielscher et al., 2012). Based on the emerging evi-
dence implicating decorin in the control of cell proliferation and growth
factor/receptor interactions (Seidler and Dreier, 2008; Ferdous et al.,
2010; Iozzo and Schaefer, 2010), we hypothesized that decorin could
also play a key role during experimental hepatocarcinogenesis. In this
study we utilized two well-established models of experimental primary
hepatocarcinogenesis using TA and DEN as carcinogens. Thioacetamide
is a promoter-type compound inducing ﬁbrosis of the liver and a concur-
rent hyper-regeneration of hepatocytes resulting in liver cancer (Becker,
1983; Camus-Randon et al., 1996). Indeed, about 70% of humanHCCs de-
velop in cirrhotic livers. In contrast, diethyl nitrosamine represents a di-
rect DNA mutagen that induces hepatic carcinomas without an
intervening ﬁbrotic remodeling (Heindryckx et al., 2009). At a molecular
level, livers exposed to TA display highly elevated level of alpha-
fetoprotein (AFP) (Fig. S4A). In contrast, DEN-induced tumors are charac-
terized with high gluthamine synthetase (GS) expression (Fig. S4B), a
target gene of β-catenin activity (Loeppen et al., 2002). Mutations of
β-catenin and/or its translocation to the nucleus (Dahmani et al., 2011),r cancer in wild-type and decorin gene-knockout (Dcn−/−) mice. Diagrams represent the
pho-PDGFRα, phospho-EGFR, phospho-MSPR, and phospho-IGF-IR normalized to the
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studied events of liver carcinogenesis. Moreover, expression analysis of
19 hepatoma cell lines revealed that AFP positive and β-catenin mutant
cancer cells represent twodifferent clusters of HCC conﬁrming our obser-
vation on distinct expression of AFP and gluthamine synthetase in TA and
DEN-induced tumors (Lee andThorgeirsson, 2002). Changes in activation
of key signalingmolecules in the two types of carcinogenesismodels cor-
roborate to existence of two types of hepatocellular carcinoma as well.
Overall, it seems that TA-induced tumors rather utilize the RTK/Ras/
MAPK pathway, whereas DEN-induced tumors prefer the β-catenin
activation.
Earlier, we reported that decorin deposits in ﬁbrotic septa (Baghy
et al., 2011), as well as around the invasive front of tumors and in the
stroma induced by thioacetamide (Baghy et al., 2013). In this type of
carcinogenesis we observed that the lack of decorin results in enhanced
tumor formation in the liver. In parallel, we wondered whether the lack
of decorin had any impact on the carcinogenesis induced in a non-
cirrhotic background provoked by DEN. In such system, decorin deﬁ-
ciency led to a moderate enhancement in tumor prevalence and size,
much less pronounced than that observed in TA-induced HCCs. In
wild-type animals, not only the amount of decorin increases in HCCs,
but also qualitative changes occur in decorin glycanation, likely due to
a longer dermatan/chondroitin sulfate chain at theN-terminus. Notably,
the decorin single glycosaminoglycan chain becomes progressively
shorter with aging (Li et al., 2013). Thus, it is possible that the longer
chain observed in the TA-induced tumors might be due to a more prim-
itive fetal-like environment characteristic of various tumor stromas.
Regardless of the carcinogen agent used, the enhanced tumor forma-
tion observed in decorin-deﬁcient livers is closely linked to a low induc-
tion of the potent cyclin-dependent kinase inhibitor p21Waf1/Cip1
(Harper et al., 1993, 1995) detected at both mRNA and protein level.
Notably, it is well established that soluble decorin protein core utilizes
p21Waf1/Cip1 to display its tumor repressor effect in most cases via both
EGFR and Met (De Luca et al., 1996; Santra et al., 1997; Buraschi et al.,
2010; Zhang et al., 2012). In our model system, lower p21Waf1/Cip1 levels
caused by decorin ablation resulted in higher activity of cyclin
dependent kinase 4 as shown by enhanced retinoblastoma phosphory-
lation at Ser780. In parallel, the action of CDK2 remained unchanged
upon decorin deﬁciency in neoplastic livers. Thus, our experimental
data in mice correlate well with reports of enhanced level and activity
of CKD4/CyclinD complexes in human HCCs (Jain et al., 2010;
Rivadeneira et al., 2010; Lu et al., 2013).
Notably, decorin-null tumors showed increased expression of
the transcription factor AP4, a known transcriptional repressor of
p21Waf1/Cip1 (Jung and Hermeking, 2009), thereby providing a mecha-
nistic explanation for the down-regulation of p21Waf1/Cip1 levels. We
further tested the distribution and subcellular localization of c-Myc, a
major transcription factor involved in the control of cell proliferation
in a variety of cancers. The rationale for this line of research is based
on the observation that soluble decorin and decorin protein core mark-
edly downregulate c-Myc levels in a variety of cancer cell lines aswell as
in orthotopic mammary carcinoma xenografts (Buraschi et al., 2010;
Iozzo and Sanderson, 2011; Neill et al., 2012b). In an agreement with
these observations we detected robust nuclear accumulation of c-Myc
in TA and DEN-evoked tumors in parallel with its decreased phosphor-
ylation at Thr58, a post-translational modiﬁcation known to destabilize
c-Myc and target it for proteasomal degradation (Buraschi et al., 2010).
In addition, c-Myc is a downstream target of β-catenin (He et al., 1998)
that plays a crucial role in hepatocarcinogenesis. In our model system,
translocation of β-catenin to the nucleus was observed in DEN-
provoked tumors as well as elevated expression of GS reﬂecting on its
efﬁciency. In contrast, TA exposure did not signiﬁcantly alter the locali-
zation of the protein, and displayed lower levels of GSmRNA. Beside the
canonical Wnt pathway, the action of β-catenin is known to be affected
by several tyrosine kinases such as c-Met (Buraschi et al., 2010), RON
(Danilkovitch-Miagkova et al., 2001) or EGFR (Hu and Li, 2010).Decorin is known tomodulate and interferewith signal transduction
via binding to growth factors and their cognate receptors at the cell sur-
face e.g. EGFR (Iozzo et al., 1999b; Csordas et al., 2000; Zhu et al., 2005),
IGF-IR (Schonherr et al., 2005; Iozzo and Sanderson, 2011), Met
(Goldoni et al., 2008). Earlier, we reported that PDGFRα activity is
markedly elevated in TA-induced hepatocarcinogenesis in a decorin-
deﬁcient background (Baghy et al., 2013). However, in our extended
dual liver carcinogenesismodel, we observed signiﬁcant basal Tyr phos-
phorylation (activation) in four RTKs, namely PDGFRα, EGFR, RON
(MSPR) and IGF-IR upon decorin deﬁciency, regardless of the carcino-
gen used. It is notable that several of these RTKs have already been im-
plicated in the pathogenesis of HCC in humans (Stock et al., 2007;
Berasain et al., 2009; Oseini and Roberts, 2009; Wu and Zhu, 2011;
Sengupta and Siddiqi, 2012; Chen et al., 2013). Surprisingly, no change
in Tyr phosphorylation ofMetwas seen in decorin-deﬁcient tumors, de-
spite decorin's ability to interactwith and downregulate this RTK. In our
animal models we discovered that a novel RTK, not previously linked to
decorin bioactivity, is MSPR, also called RON, the receptor for the hepa-
tocyte growth factor-like protein. This is interesting insofar as RON has
been implicated in the development and progression of human HCCs
(Chen et al., 1997; Cho et al., 2011).
Downstream of RTKs, the Ras/MEK/ERK and PI3K/Akt/mTOR repre-
sent the major and most studied pathways in several types of cancers
including HCC (Villanueva et al., 2007; Whittaker et al., 2010). We ob-
served a striking elevation in Erk1/2 phosphorylation in the absence of
decorin in liver tumors, even when it was not induced in wild-type an-
imals upon DEN exposure. These changes were the most signiﬁcant
ones we observed upon ablation of decorin in our experimental set-
up. In addition, phosphorylation of Akt markedly increased in Dcn−/−
liver cancers when compared to that of wild-type animals. The active
form of Akt is known to inactivate GSK3β via phosphorylation
(Grimes and Jope, 2001; Jacobs et al., 2012). However, no difference
in Phospho-GSK3β level between wild type and decorin-null liver tu-
mors was seen by immunoblottings. Indeed, and in contrast to our pre-
diction, decreased phosphorylation of c-Myc and β-catenin detected in
the Dcn−/− carcinogen-exposed livers should reﬂect on the enhanced
inactivation of GSK3β (Iozzo and Sanderson, 2011). Of note, GSK3β is
a key molecule linking several signaling pathways such as those ema-
nating from Wnt and RTKs. Thus, its activity is precisely regulated by
various processes. Beside inactivating phosphorylation at Ser9, the ac-
tion of GSK3β is enhanced by its phosphorylation at Tyr216. This acti-
vating phosphorylation is known to be hindered by EGF or insulin
(Grimes and Jope, 2001). It is plausible that the decreased GSK3β func-
tion observed in decorin-null liver cancers is a result of its attenuated
activating phosphorylation provoked by the higher activity of EGFR.
Decorin seems to be more effective in TA-induced liver cancer than
in DEN-evoked one in non-cirrhotic background as its lack causes
much pronounced tumorigenesis upon TA exposure when compared
to wild type mice. We do not know whether collagen bound decorin is
effective in interfering with signaling or associatingwith cell surface re-
ceptors. In cirrhotic liver decorin is accumulated along the ﬁbrotic septa
as well as around tumors, while there is much less decorin observed in
DEN-induced HCCs. Of note, enhanced degradation of the extracellular
matrix by MMPs is a typical process in both ﬁbrogenesis (Dudas et al.,
2001; Guo and Friedman, 2007) and carcinogenesis (Okazaki and
Inagaki, 2012; Lempinen et al., 2013). As a consequence, we hypothe-
size that decorin could be released from collagens resulting in a local ac-
cumulation of the soluble proteoglycan at the invasive front of tumors.
In this manner, as the amount of decorin already increased during cir-
rhosis, its local concentration around the tumors is much higher in
HCCs with cirrhosis than in carcinomas developed in a non-cirrhotic
surrounding leading to more pronounced tumor repression by decorin
in TA-provoked cancer.
In conclusion, our novel ﬁndings indicate that a complex network of
intervening cellular signaling events is present in our experimental
hepatocarcinogenesis model. The ablation of decorin leads to enhanced
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cert transmit growth-promoting and pro-survival downstream signal-
ing in an environment deplete of a powerful pan-RTK repressor.
According to our working model (Fig. 8), the de-repression of several
RTKs by a tumor stroma devoid of decorinwould evoke a chronic activa-
tion of theRas/MEK/ERKpathway, themain pathwayof signal transduc-
tion found in our HCCs. In addition, Akt activation together with the
observed hindered degradation of c-Myc and β-catenin provoked by
decorin deﬁciencywould play a contributing role aswell (Fig. 8).Within
the nucleus, c-Myc induces AP4 expression a known transcriptional re-
pressor of p21Waf1/Cip1. Consequently, reduced p21Waf1/Cip1 levels would
be insufﬁcient to inactivate CDK4/CyclinD1. In this way, Rb phosphory-
lation would culminate in E2F release thereby allowing the cell to by-
pass the restriction point in G1 phase (Fig. 8).
Collectively, our ﬁndings provide novel information regarding the
role of decorin in liver cancer and offer a mechanistic explanation for
its in vivo biological activity. As decorin is a natural product, which
has been detected in the circulation following sepsis and cancer
(Merline et al., 2011) our results support the concept that decorin pro-
teoglycan or protein core could be utilized in future studies as an antitu-
mor agent useful in the battle against liver cancer.
4. Experimental procedures
4.1. Generation of decorin-null mice
All animal experiments were conducted according to the ethical
standards of the Animal Health Care and Control Institute, Csongrád
County, Hungary, permit No. XVI/03047-2/2008. Decorin deﬁcientFig. 8. Action of decorin on cellular signaling in experimental liver cancer. In the extracellula
tyrosine kinases (RTK). These interactions interfere with downstream signaling pathways, such
can be an outcome of crosstalk between the different growth factor receptors. The action of GS
blockade to display its tumor-repressor effect. When decorin is not present, c-Myc translocation
accumulate in enhanced retinoblastoma phosphorylation by CDK4 and push the cell cycle tow
activated protein kinase/ERK kinase.mice were generated as previously described (Danielson et al., 1997).
In brief, the inactivation of the decorin gene was achieved by targeted
disruption of the exon 2 inserting a PGK-Neo cassette. Two male and
two female C57Bl/6 mice heterozygous for decorin gene (Dcn−/−)
which were backcrossed into C57Bl/6 background for nine generations,
were bred until homozygosity. The genotype of the offspringwas deter-
mined by PCR. Tail DNA was isolated by using high salt method. Subse-
quently 3 primers were applied, sense and antisense speciﬁc for the
exon 2, and one corresponding to the PGK-Neo cassette. PCR products
were analyzed by 2% agarose gel electrophoresis.
4.2. Induction of experimental hepatocarcinogenesis
For induction of liver cancer in a cirrhotic background, we utilized a
total of 24 onemonth-oldmalemice. Fifteenwild-type, and 15 decorin-
null (Dcn−/−) animals with C57Bl/6 background were exposed to
thioacetamide (TA) dissolved in drinking water (150 mg/l). To obtain
fully-developed hepatocellular carcinoma, animals were subjected to
TA treatment for 7 months. Age-matched untreated animals with iden-
tical genetic background served as controls. Mice were terminated after
7 months of thioacetamide exposure by cervical dislocation in ether
anesthesia. Hepatocarcinogenesis in non-cirrhotic livers was induced
by a single high-dose intraperitoneal injection of diethyl nitrosamine
(DEN, 15 μg/g body weight) at the age of 15 days. Ten wild type and
10 Dcn−/− mice were utilized for this experiment and 5–5 age-
matched untreated animals served as controls. Formation of hepatocel-
lular carcinoma appeared 9 months after DEN injection. At termination,
body weight and liver weight of the animals were measured and the
number of macroscopically detectable tumors was counted. Half of ther environment, decorin may bind to growth factors (such as PDGF) and various receptor
as Akt/GSK3β or Ras/MEK/ERK. Changes in ERK1/2 in the presence or absence of decorin
K3β leads to β-catenin and c-Myc degradation. Decorin utilizes p21WAF1/CIP1 for cell-cycle
to the nucleus induces the expression of AP4 that ﬁnally blocks p21WAF1/CIP1. These events
ard to S phase. GF = growth factor; GSK3 = glycogen synthase kinase 3; MEK, mitogen-
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ﬁxed in 10% formaldehyde and embedded in parafﬁn for histological
analysis. Formalin-ﬁxed parafﬁn-embedded sections were solubilized
in xylene and stained with hematoxylin and eosin, or processed further
for immunohistochemistry. Stained sections were used for histological
diagnosis. To determine the tumor volume of livers, HE stained sections
were scanned by Panoramic Scan (3D Histech Ltd., Budapest, Hungary).
The length and width of tumors in each section were determined with
the help of Pannoramic viewer program (3D Histech Ltd.) Tumor
volume was calculated as V = (width (mm)2 × length (mm)*π) / 6.
4.3. Real-time PCR (qPCR)
For qPCR, total RNAwas isolated from frozen livers. After homogeni-
zation in liquid nitrogen total RNAwas puriﬁed using the RNAeasyMini
Kit (Qiagen, Hilden, Germany), according to the protocol provided by
the manufacturer. The yield and purity of RNA were estimated by an
ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington,
DE, USA). The integrity and size distribution of the total RNA puriﬁed
were analyzed using Experion RNA Chips and the Experion Automated
Electrophoresis Station (Bio-Rad, Hercules, CA). Complementary DNAs
(cDNAs) were generated from 1 μg of total RNA by M-MLV Reverse
Transcriptase kit (Invitrogen by Life technologies Carlsbad, CA, USA)
according to the instructions of the supplier. Real-time PCR was per-
formed in an ABI Prism 7000 Sequence Detection System (Applied
Biosystems by Life Technologies, Carlsbad, CA, USA), using ABI TaqMan
Gene Expression Assays for mouse p21WAF1/CIP1 (CDKN1A, Assay ID:
Mm00432448_m1), AP4 (Assay ID: Mm00473137_m1), gluthamine
synthetase (Assay ID: Mm00725701_s1), AFP (Mm00431715_m1) ap-
plying 18S rRNA as endogenous control (Part No. 4319413E) according
to the manufacturer's protocol. All samples were run in duplicates in
20 μl total volume containing 50 ng cDNA using TaqMan Universal
PCRMasterMix (Part No. 4324018, Applied Biosystems by Life Technol-
ogies). The thermal cycle conditions for reactionswere as follows: dena-
turation for 10 min at 95 °C, 40 cycles of denaturation at 95 °C for 15 s
and annealing at 60 °C for 1 min. Results were obtained as threshold
cycle (CT) values. Relative expression levels were calculated by using
the 2−ΔΔCT method.
4.4. Immunostaining
Formalin-ﬁxed parafﬁn-embedded sections were solubilized in
xylene and ethanol, then washed with distilled H2O for 5 min. Antigen
retrieval was performed in a pressure cooker using TRIS-EDTA buffer
(10 mM TRIS, 1 mM EDTA, 0.05% Tween 20, pH 9) for 20 min. After
cooling, slides were washed 3 times in PBS with 0.05% Tween20
(PBST). Next, endogenous peroxidase was inactivated by addition of
10% H2O2 dissolved in methanol for 10 min. After washing with PBST,
5 w/v% bovine serum albumin (BSA)/PBS containing10% normal
serum was applied for 1 h to prevent any nonspeciﬁc binding. Primary
antibodies were applied overnight at 4 °C. The next day, slides were
washed 3 times in PBST, and then incubatedwith appropriate secondary
antibodies conjugated eitherwith horse reddish peroxidase or biotin for
1 h. A detailed list of primary and secondary antibodies and their
appropriate dilutions is provided in Supplementary Table 1. For biotin-
labeled secondary antibodies, signals were ampliﬁed by Vectastain
ABC kit (Vector Laboratories, Burlingame, CA) following the instructions
of the supplier. After washing, signals were visualized by using 3,3-
diaminobenzidine tetrahydrochloride (DAB) substrate chromogen solu-
tion (Dako, Glostrup, Denmark) followed by counterstaining with
hematoxylin. For decorin immunostaining, frozen sections of the liver
were ﬁxed in ice-cold methanol for 20 min. Next, slides were washed
in PBS, blocked with 5 w/v% BSA/PBS containing 10 v/v% nonimmune
serum of secondary antibody at 37 °C for 30 min. After washing, sec-
tions were incubated with the primary antibodies diluted in 1:50 in
PBS containing 1 w/v% BSA, at 4 °C for 16 h. Appropriate ﬂuorescentsecondary antibodies were applied at room temperature for 30 min.
Nuclei were stained with 4′-6′-diamidino-phenylindole (DAPI).
Pictures were taken by a Nikon Eclipse E600 microscope with the help
of Lucia Cytogenetics version 1.5.6 program, or by a confocal laser scan-
ning microscope (MRC-1024, Bio-Rad Richmond, CA). Details of anti-
bodies and their appropriate dilutions are found in Supplementary
Table 1.
4.5. Phospho-RTK array and Western blot
Total proteinswere extracted from frozen liver tissues. After homog-
enization in liquid nitrogen 1 ml of lysis buffer was added to the sam-
ples (20 mM TRIS pH 7.5, 2 mM EDTA, 150 mM NaCl, 1% Triton-X100,
0.5% Protease Inhibitor Cocktail (Sigma, St. Luis, MO) 2 mM Na3VO4,
10 mM NaF). After incubation for 30 min on ice, samples were centri-
fuged at 15,000 g for 20 min. Supernatants were kept and protein con-
centrationsweremeasured as described before by Bradford (1976). The
activities of phospho-receptor tyrosine kinases (Phospho-RTKs) were
assessed by their relative levels of phosphorylation using the Proteome
Proﬁler Array (R&D Systems, Minneapolis, MN, USA) according to the
manufacturer's instructions. Pooled samples of ﬁve livers from the
same experimental group were homogenized in lysis buffer (described
above) and adjusted to 1.2 μg protein/μl lysate. Signals were developed
by incubating the membrane in SuperSignal West Pico Chemilumines-
cent Substrate Kit (Pierce/Thermo Scientiﬁc,Waltham,MA), and visual-
ized on a Kodak Image Station 4000MM Digital Imaging System.
For Western blot, 30 μg of total proteins was mixed with loading
buffer containing β-mercaptoethanol and was incubated at 99 °C for
5 min. Denatured samples were loaded onto a 10% polyacrylamide gel
andwere run for 30 min at 200 V on aMini Protean vertical electropho-
resis equipment (Bio-Rad, Hercules, CA). Proteins were transferred to
PVDF membrane (Millipore, Billerica, MA) by blotting for 1.5 h at
100 V. Ponceau staining was applied to determine blotting efﬁciency.
Membranes were blocked with 3 w/v% non-fat dry milk (Bio-Rad) in
TBS for 1 h followed by incubation with the primary antibodies at 4 °C
for 16 h. Ponceau staining served as loading control. Membranes were
washed 5 timeswith TBS containing 0.05 v/v% Tween-20, thenwere in-
cubatedwith appropriate secondary antibodies for 1 h. Signalswere de-
tected by SuperSignal West Pico Chemiluminescent Substrate Kit
(Pierce/Thermo Scientiﬁc), and visualized by Kodak Image Station
4000MM Digital Imaging System. Western blot analyses were per-
formed 3 independent times, running the samples in duplicates. The
density of the bands wasmeasured by the Kodak Image Station. For an-
tibody speciﬁcations and dilutions applied see Supplementary Table 1.
4.6. Statistical analysis
All statistical analyses were made with GraphPad Prism 4.03 soft-
ware (Graphpad Software Inc.). Data were tested for normal distribu-
tion by D'Agostino and Pearson's omnibus normality test. Signiﬁcance
of changes was tested by non-parametric tests (Mann–Whitney) or
Students' t-tests depending on the distribution of the data. The differ-
ence between wild type and Dcn−/− groups in tumor prevalence was
tested for signiﬁcance by χ2-test. The independent experimental sets
were compared for reproducibility. Only reproducible signiﬁcant
changes were considered as signiﬁcant. Signiﬁcance was declared at
the standard p b 0.05 level.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.matbio.2013.11.004.
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